E-cigarette (EC) use continues to increase among youth, and EC may be detrimental to youth respiratory health. Public health officials and the Food and Drug Administration (FDA) can now regulate ECs. The proposed study uses naturalistic assessments called ecological momentary assessment (EMA) to understand how ECs use may impact the respiratory health of youth and young adult users compared to never-using peers.
Using a prospective longitudinal design, 150 youth and young adults aged 18-25 years (100 exclusive-EC users; 50 never-users) will complete 5 sessions (baseline, 3-,6-, 9-, and 12-months). Sessions will include naturalistic measures such as measures of respiratory health, questionnaires, and nasal epithelial lining fluid (NELF) nasal samples. To assess acute changes in pulmonary functioning related to tobacco product use, participants will complete twice daily EMA and home-based spirometry for the 2 weeks following the Day 1 session and the 2 weeks prior to each follow-up zoom session. Never-users will participate in a brief 15-30-minute individual interview consisting of questions related to reasons for never-EC use and other protective factors that will be used to build future prevention messaging.
Study Type
OBSERVATIONAL
Enrollment
115
The Ohio State University
Columbus, Ohio, United States
Spirometry to Measure the Change From Baseline in Forced Vital Capacity (FVC)
Participants will complete twice daily home-based spirometry (a pulmonary function diagnostic test) for the 2 weeks prior to each follow-up session.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Spirometry to Measure the Change From Baseline in Forced Expiratory Volume (FEV)
Participants will complete twice daily home-based spirometry (a pulmonary function diagnostic test) for the 2 weeks prior to each follow-up session.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Level of Dependence by Product Type Will be Examined.
Changes in product use evaluated with an evaluation of the changes in dependence using the Hooked on Nicotine Checklist (HONC). Scores range from 0 to 10 with higher values indicating greater levels of dependence.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-6
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine).
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-8
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - TNF-alpha
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-4
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-5
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-10
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - IL-13
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - TARC
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - Eotaxin
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - MCP-1
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - MCP-4
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month
Respiratory Health Measures by Nasal Swab - Cotinine
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
Time frame: Baseline, 3-month, 6-month, 9-month, 12-month